Renovascular hypertension from the BCR‐ABL tyrosine kinase inhibitor ponatinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Renovascular hypertension from the BCR‐ABL tyrosine kinase inhibitor ponatinib

Published:2020-03-16 Issue:4 Volume:22 Page:678-682
ISSN:1524-6175
Container-title:The Journal of Clinical Hypertension
language:en
Short-container-title:J Clin Hypertens

Author:

Amin Syed O.¹,Ruzicka Marcel¹,Burns Kevin D.¹,Bence‐Bruckler Isabelle A.²,Ryan Stephen E.³,Hadziomerovic Adnan³,Hiremath Swapnil¹⁴^ORCID

Affiliation:

1. Division of Nephrology Department of Medicine University of Ottawa Ottawa ON Canada

2. Division of Hematology Department of Medicine University of Ottawa Ottawa ON Canada

3. Division of Vascular/Interventional Radiology Department of Medical Imaging University of Ottawa Ottawa ON Canada

4. Clinical Epidemiology Program Ottawa Hospital Research Institute Ottawa ON Canada

Funder

Department of Medicine, University of Ottawa

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jch.13843

Reference9 articles.

1. Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition

2. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

3. Renal failure associated with tyrosine kinase inhibitors—Case report and review of the literature

4. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia

5. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management;Cardio-Oncology;2023-12-12

2. The progress of small-molecules and degraders against BCR-ABL for the treatment of CML;European Journal of Medicinal Chemistry;2022-08

3. Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics;Drug Discovery Today;2020-12

4. BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon;Leukemia Research Reports;2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3